Merck’s Head of Human Resources Mirian M. Graddick-Weir to Retire; Steven C. Mizell Will Assume Role on Oct. 1
August 07 2018 - 4:30PM
Business Wire
Merck (NYSE: MRK), known as MSD outside the United States and
Canada, today announced the retirement effective November 30, 2018
of its chief human resources officer Mirian M. Graddick-Weir,
following 12 years of service with the company. She will be
succeeded by Steven C. Mizell, who will join the company in October
2018.
Graddick-Weir joined Merck in 2006. During her tenure, she has
been instrumental in leading global and transformational change
across the business and the human resources function as well as
strengthening the diverse pipeline of talent. She will remain with
the company until November and will work closely with Mizell to
ensure a successful transition. “Mirian has made significant,
enduring contributions as a member of Merck’s senior leadership
team,” said Kenneth C. Frazier, Merck chairman and chief executive
officer. “Her work has positioned us to better attract and develop
the workforce of the future.”
Mizell will join Merck from Monsanto, where he served as
executive vice president and chief human resources officer since
2004. He will be responsible for the company’s global human
resources function and will serve as a member of Merck’s Executive
Committee. “We are pleased to welcome Steve as our new chief human
resources officer,” said Frazier. “His experience in leading human
resources organizations, counseling leaders and board of directors
and maximizing human capital around the world will make him a
valuable contributor to our team.”
Throughout his career, Mizell has held positions of increasing
responsibility across a range of disciplines within the human
resources field. Prior to his role at Monsanto, Mizell was senior
vice president and chief corporate resources officer for Advance
PCS, a large prescription benefit plan administrator. He also was
senior vice president and chief human resources and real estate
officer for the technology company Zilog, Inc. Mizell is a Board
Member of Oshkosh Corporation, a manufacturer of specialty vehicles
and access equipment. He earned a Bachelor of Science in Industrial
Management from the Georgia Institute of Technology and a Master of
Science in Management and Public Policy Analysis from Carnegie
Mellon University.
“Given Merck’s legacy, values and impact on the world, I
couldn’t be more honored to join the company,” said Mizell. “I look
forward to contributing to the Executive Committee and the
organization at large.”
“I am proud of the Merck Human Resources team and its
contributions to the company during my 12 years leading this
world-class HR organization,” said Graddick-Weir. “I will leave
Merck feeling satisfied that I have contributed to its long-term
mission and improving its most important resource, which is
people.”
About Merck
For more than a century, Merck, a leading global
biopharmaceutical company known as MSD outside of the United States
and Canada, has been inventing for life, bringing forward medicines
and vaccines for many of the world’s most challenging diseases.
Through our prescription medicines, vaccines, biologic therapies
and animal health products, we work with customers and operate in
more than 140 countries to deliver innovative health solutions. We
also demonstrate our commitment to increasing access to health care
through far-reaching policies, programs and partnerships. Today,
Merck continues to be at the forefront of research to advance the
prevention and treatment of diseases that threaten people and
communities around the world - including cancer, cardio-metabolic
diseases, emerging animal diseases, Alzheimer’s disease and
infectious diseases including HIV and Ebola. For more information,
visit www.merck.com and connect with us
on Twitter, Facebook, Instagram, YouTube
and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc.,
Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J.,
USA (the “company”) includes “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These statements are
based upon the current beliefs and expectations of the company’s
management and are subject to significant risks and uncertainties.
If underlying assumptions prove inaccurate or risks or
uncertainties materialize, actual results may differ materially
from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general
industry conditions and competition; general economic factors,
including interest rate and currency exchange rate fluctuations;
the impact of pharmaceutical industry regulation and health care
legislation in the United States and internationally; global trends
toward health care cost containment; technological advances, new
products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory
approval; the company’s ability to accurately predict future market
conditions; manufacturing difficulties or delays; financial
instability of international economies and sovereign risk;
dependence on the effectiveness of the company’s patents and other
protections for innovative products; and the exposure to
litigation, including patent litigation, and/or regulatory
actions.
The company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise. Additional factors that could cause
results to differ materially from those described in the
forward-looking statements can be found in the company’s 2017
Annual Report on Form 10-K and the company’s other filings with the
Securities and Exchange Commission (SEC) available at the SEC’s
Internet site (www.sec.gov).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180807005651/en/
MerckMedia:Claire Gillespie, 267-305-0932orInvestors:Teri Loxam,
908-740-1986
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024